Abstract

PurposeWe assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. MethodsRetrospective cohort data on 18,935 BRCA1 and 12,339 BRCA2 female pathogenic variant carriers of European ancestry were available. Three versions of a 313 single-nucleotide polymorphism (SNP) BC PRS were evaluated based on whether they predict overall, estrogen receptor (ER)–negative, or ER-positive BC, and two PRS for overall or high-grade serous EOC. Associations were validated in a prospective cohort. ResultsThe ER-negative PRS showed the strongest association with BC risk for BRCA1 carriers (hazard ratio [HR] per standard deviation=1.29 [95% CI 1.25–1.33], P=3×10−72). For BRCA2, the strongest association was with overall BC PRS (HR=1.31 [95% CI 1.27–1.36], P=7×10−50). HR estimates decreased significantly with age and there was evidence for differences in associations by predicted variant effects on protein expression. The HR estimates were smaller than general population estimates. The high-grade serous PRS yielded the strongest associations with EOC risk for BRCA1 (HR=1.32 [95% CI 1.25–1.40], P=3×10−22) and BRCA2 (HR=1.44 [95% CI 1.30–1.60], P=4×10−12) carriers. The associations in the prospective cohort were similar. ConclusionPopulation-based PRS are strongly associated with BC and EOC risks for BRCA1/2 carriers and predict substantial absolute risk differences for women at PRS distribution extremes.

Highlights

  • Pathogenic variants in BRCA1 and BRCA2 are associated with high risk of developing breast and ovarian cancers.[1,2] A recent study of BRCA1/2 carriers estimated the average risk of developing breast cancer by age 80 years to be 72% for BRCA1 and 69% for BRCA2 carriers.[2]

  • The ER-negative Polygenic risk scores (PRS) showed the strongest association with BC risk for BRCA1 carriers

  • The high-grade serous PRS yielded the strongest associations with epithelial ovarian cancer (EOC) risk for BRCA1 (HR = 1.32 [95% CI 1.25–1.40], P = 3×10−22) and BRCA2 (HR = 1.44 [95% CI 1.30–1.60], P = 4×10−12) carriers

Read more

Summary

Introduction

Pathogenic variants in BRCA1 and BRCA2 are associated with high risk of developing breast and ovarian cancers.[1,2] A recent study of BRCA1/2 carriers estimated the average risk of developing breast cancer by age 80 years to be 72% for BRCA1 and 69% for BRCA2 carriers.[2] Corresponding ovarian cancer risks were 44% for BRCA1 and 17% for BRCA2 carriers This and previous studies have demonstrated that cancer risks for BRCA1/2 carriers increase with an increasing number of affected first- or second-degree relatives,[2] suggesting genetic or other familial factors modify cancer risks for BRCA1/2 carriers. Consistent with this observation, common breast and ovarian cancer susceptibility single-nucleotide polymorphisms (SNPs), identified through genome-wide association studies (GWAS) in the general population, have been shown to modify breast and ovarian cancer risks for BRCA1/2 carriers.[3,4,5,6,7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call